Monotherapy trials in unselected patients with EGFR inhibitors indicate that there is an EGFR-driven minority ESCC subgroup who gain survival, symptomatic control and health-related quality of life benefits from EGFR inhibitors [10, 11]. Here, EGFR is linked to esophageal squamous cell carcinoma.